Study guide

16.3 Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology

IJCAHPO Certified Ophthalmic Medical Technologist COMT

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The COMT Examination, Eligibility & Certification Requirements

1.1 The 190-Question Multiple-Choice Examination & the 22 Official Content Areas 1.2 The COT Skill Evaluation & the COMT Performance Test 1.3 Eligibility Pathways, Fees, Timelines & Recertification

2 Chapter 2: General Medical Knowledge I — Ocular Anatomy & Physiology

2.1 Orbit, Eyelids, Lacrimal System, Conjunctiva & Extraocular Muscles 2.2 Cornea, Sclera, Anterior Chamber, Angle, Aqueous Dynamics & Crystalline Lens 2.3 Uvea, Retina, Vitreous, Optic Nerve, Ocular Circulation & the Visual Pathway

3 Chapter 3: General Medical Knowledge II — Eye Disease, Systemic Manifestations, Terminology & Safety

3.1 Frequently Encountered Eye Conditions by Structure & Inflammation Versus Infection 3.2 Body Systems & the Ocular Manifestations of Systemic Disease 3.3 Medical Terminology, Approved Abbreviations, Hazardous Waste & Clinic Safety

4 Chapter 4: Ophthalmic History Taking & Clinical Documentation

4.1 The Five History Domains: Ocular, Medical, Medication, Social & Family 4.2 Charting Conventions, Scribing & the Electronic Medical Record

5 Chapter 5: Visual Assessment, Accommodative Testing & Low Vision

5.1 Measuring Acuity at Every Level & in Preliterate, Illiterate and Non-Verbal Patients 5.2 Stereoacuity, Near Point of Accommodation, Near Point of Convergence & the AC/A Ratio 5.3 Low Vision Assessment, Magnification Calculation & Device Instruction

6 Chapter 6: Tonometry, Keratometry & Pupil Measurement

6.1 Goldmann Applanation Tonometry: Technique, Sources of Error & the Imbert-Fick Principle 6.2 Hand-Held Applanators, Non-Contact Tonometry, Rebound Tonometry & Disinfection 6.3 Manual & Automated Keratometry: Technique, Readings and Interpretation 6.4 Pupil Measurement, Shape, Reactivity & Evaluating Anisocoria

7 Chapter 7: Lensometry, Spectacle Optics & Prescription Analysis

7.1 Manual Lensometry: Eyepiece Focus, Neutralising Sphere, Cylinder & Axis 7.2 Neutralising Reading Adds: Bifocal, Trifocal, Progressive & Determining the Near Add 7.3 Identifying & Measuring Prism: Ground-In, Decentration, Fresnel Press-On & Slab-Off 7.4 Transposition, Spherical Equivalent, Vertex Distance & Prescription Components 7.5 The Geneva Lens Clock, Lens Materials, Progressive Markings & Spectacle Adjustment

8 Chapter 8: Refraction, Retinoscopy & Refinement

8.1 Autorefraction, Refractive Error Types & Establishing an Objective Starting Point 8.2 Streak Retinoscopy: With Motion, Against Motion, Neutralisation & Working Distance 8.3 Subjective Refinement: Fogging, Jackson Cross Cylinder, Duochrome & Binocular Balance 8.4 Near Add Determination, Vertex Recording & Refraction in Difficult Situations

9 Chapter 9: Ocular Motility, Strabismus & Advanced Optics

9.1 Ocular Kinematics: Ductions, Versions, Vergences, Hering's & Sherrington's Laws 9.2 Quantitative Strabismus Measurements: Alternate Cover Test, Prism Cover Test & Lancaster Red-Green / Hess Screen 9.3 Cranial Nerve Palsies (CN III, IV, VI), Restrictive Myopathies & Forced Duction Testing 9.4 Clinical Optics, Prentice's Rule, Slab-Off Prisms & Wavefront Aberrations

10 Chapter 10: Sensory Fusion Testing, Nystagmus, Amblyopia & Vergence Therapy

10.1 Sensory Fusion Testing: Worth 4-Dot, Maddox Rod & Bagolini Lenses 10.2 Hirschberg, Krimsky, Brückner & Fusional Vergence Amplitudes 10.3 Nystagmus, Amblyopia Therapy & Convergence Training

11 Chapter 11: Advanced Visual Fields & Neuro-Ophthalmic Evaluation

11.1 Amsler Grid & Confrontation Visual Field Testing 11.2 Automated Static Perimetry: HFA Strategies (SITA Standard, SITA Fast), Reliability Indices & Statpac Analysis 11.3 Visual Field Defect Patterns: Glaucomatous Nerve Fiber Bundle Deficits vs. Retinal Pathology 11.4 Kinetic Perimetry (Goldmann Perimetry) & Neurological Visual Pathway Defect Localization 11.5 Pupillary Pathways, RAPD Quantitation with Neutral Density Filters & Pharmacologic Testing

12 Chapter 12: Supplemental Testing — Glare, PAM, Colour Vision, Tear Film & Slit Lamp Technique

12.1 Glare Testing, Potential Acuity Meter & Contrast Sensitivity 12.2 Colour Vision: Pseudoisochromatic Plates, Farnsworth-Munsell D-15 & the 100-Hue Test 12.3 Tear Film Assessment: Schirmer, Tear Break-Up Time, Vital Dyes & Corneal Sensitivity 12.4 Slit Lamp Technique, Slit Lamp Lenses, Direct Ophthalmoscopy & Pen Light Examination 12.5 Exophthalmometry, Head & Posture Assessment and Wavefront Diagnostics

13 Chapter 13: Full-Field Electroretinography & ISCEV Protocols

13.1 Retinal Neurophysiology & Electrophysiologic Origin of Waveforms 13.2 ISCEV Standard Full-Field ERG Protocol & Electrode Systems 13.3 Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response 13.4 Light-Adapted (Photopic) Testing: Cone Response, 30-Hz Flicker & Oscillatory Potentials

14 Chapter 14: Advanced Electrophysiologic Testing (mfERG, PERG, VEP, EOG)

14.1 Multifocal Electroretinogram (mfERG): Topographic Retinal Mapping 14.2 Pattern Electroretinogram (PERG): Ganglion Cell & Macular Function 14.3 Visual Evoked Potentials (VEP): Flash, Pattern & Visual Pathway Integrity 14.4 Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics

15 Chapter 15: Fluorescein Angiography Principles & Technique

15.1 Fluorescein Angiography Principles, Exciter/Barrier Filters & Injection Protocol 15.2 Normal Transit Phases & Retinal/Choroidal Circulation Hemodynamics 15.3 Adverse Reactions, Patient Safety & Emergency Management

16 Chapter 16: Angiographic Interpretation & Pathology

16.1 Hyperfluorescence Mechanisms: Leakage, Staining, Pooling, Window Defects & Autofluorescence 16.2 Hypofluorescence Mechanisms: Vascular Non-Perfusion & Blocking Defects 16.3 Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology

17 Chapter 17: Advanced Fundus Imaging & Optical Coherence Tomography

17.1 Fundus Autofluorescence (FAF) & Ultra-Widefield Fundus Imaging 17.2 Spectral-Domain and Swept-Source OCT: Retinal Layer Architecture & Quantitative Analysis 17.3 Enhanced Depth Imaging (EDI-OCT) & Anterior Segment OCT (AS-OCT) 17.4 Optical Coherence Tomography Angiography (OCTA): Chorioretinal Plexuses & Biomarkers

18 Chapter 18: Ophthalmic Photography & Videography

18.1 The Fundus Camera: Optics, Alignment & Correcting Artefacts 18.2 Standard Fundus Photography: ETDRS Fields, Stereo Pairs, Red-Free & Wide-Field Imaging 18.3 Slit Lamp & Anterior Segment Photography 18.4 External Photography, Nine-Gaze Motility Documentation & Image Management

19 Chapter 19: Ophthalmic Echography (A-Scan, B-Scan & UBM)

19.1 Physics of Ophthalmic Ultrasound, Acoustic Impedance & Probe Transducers 19.2 Standardized Diagnostic A-Scan: Acoustic Spikes, Tissue Reflectivity & Attenuation 19.3 Diagnostic B-Scan Echography: Topographic, Kinetic & Quantitative Vitreoretinal Evaluation 19.4 Ultrasound Biomicroscopy (UBM): Anterior Segment Anatomy, Angle Pathology & Ciliary Body Imaging

20 Chapter 20: Biometry, Topography & Corneal Analysis

20.1 Optical Biometry vs. Immersion/Contact Ultrasound Biometry 20.2 Intraocular Lens (IOL) Power Calculation Formulas & Post-Refractive Adjustments 20.3 Corneal Topography, Scheimpflug Tomography & Keratoconus Screening 20.4 Corneal Pachymetry, Endothelial Specular Microscopy & Anterior Chamber Depth

21 Chapter 21: Rigid Gas Permeable & Specialty Lens Fitting

21.1 Rigid Gas Permeable (RGP) Material Properties, Dk/t & Oxygen Permeability 21.2 RGP Base Curve Selection, Diagnostic Fitting & Fluorescein Pattern Evaluation 21.3 Scleral Contact Lens Design, Sagittal Depth Fitting & Clearance Evaluation 21.4 Keratoconus, Irregular Corneas & Hybrid Contact Lens Systems

22 Chapter 22: Toric, Multifocal, Therapeutic Lenses & Complications

22.1 Toric Soft Contact Lens Dynamics, Stabilization Techniques & LARS Rule 22.2 Presbyopic & Multifocal Contact Lens Systems: Simultaneous vs. Translating Designs 22.3 Therapeutic Bandage Contact Lenses, Amniotic Membranes & Orthokeratology 22.4 Contact Lens-Induced Pathology, Giant Papillary Conjunctivitis & Infectious Keratitis

23 Chapter 23: Ocular Pharmacology

23.1 Routes of Drug Delivery, Prescription Components & Instillation Technique 23.2 Mydriatics, Cycloplegics, Anaesthetics & Diagnostic Agents 23.3 Glaucoma Medications: Classes, Mechanisms & Side Effects 23.4 Anti-Infectives, Corticosteroids, NSAIDs, Allergy Agents, Lubricants, Supplements & Anti-VEGF

24 Chapter 24: Microbiology & Ocular Specimen Collection

24.1 Types of Microorganisms & Pathways of Disease Transmission 24.2 Assisting with Conjunctival & Corneal Specimen Collection

25 Chapter 25: Anterior Segment, Glaucoma & Refractive Surgery

25.1 Advanced Phacoemulsification, Surgical Steps, Fluidics & Complication Management 25.2 Premium Intraocular Lenses: Toric, Multifocal, EDOF & Lens Exchange 25.3 Glaucoma Surgical Procedures: Trabeculectomy, Aqueous Shunts & MIGS Devices 25.4 Laser In Situ Keratomileusis (LASIK), PRK, SMILE & Phakic IOLs

26 Chapter 26: Vitreoretinal, Corneal & Trauma Surgery

26.1 Pars Plana Vitrectomy (PPV), Scleral Buckling & Intraocular Tamponades (Gas/Silicone Oil) 26.2 Corneal Transplantation: Penetrating Keratoplasty (PKP) & Lamellar Keratoplasty (DSAEK, DMEK, DALK) 26.3 Ocular Trauma Repair: Open Globe Management, Hyphema, Vitreous Loss & Endophthalmitis Protocol

27 Chapter 27: Surgical Asepsis, Instrumentation & Laser Procedures

27.1 Operating Room Sterilization, Aseptic Field Maintenance & Universal Precautions 27.2 Microsurgical Instrumentation, Maintenance & Sharps Safety 27.3 Ophthalmic Laser Physics, Delivery Systems & Safety (Nd:YAG, Argon/FD-Nd:YAG, SLT)

28 Chapter 28: Ophthalmic Patient Services & Education

28.1 Communicating with Patients, Families and Colleagues, and Handling Dissatisfaction 28.2 Patient Education & Counselling on Conditions, Medications, Tests and Results 28.3 Ophthalmic Emergencies, First Aid, Vital Signs & CPR 28.4 Triage, Urgency-Based Scheduling, Patient Flow & Telephone Management 28.5 Dressings and Shields, Prosthetics, Legal Forms, Referrals & Reimbursement Support

29 Chapter 29: Clinic Operations — Equipment Maintenance, Ethics, Coding & Compliance

29.1 Equipment Maintenance, Calibration, Emergency Equipment & Inventory 29.2 Confidentiality, Informed Consent, Scope of Practice & Ethical Standards 29.3 Coding, Scribing Compliance, Quality Assurance & Regulatory Requirements

16.3 Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology

Key Takeaways Explain This Topic AI

Indocyanine green (ICG) dye operates in the near-infrared spectrum with peak absorption at 805 nm and peak fluorescence emission at 835 nm, allowing deep penetration through retinal pigment epithelium (RPE), macular xanthophyll, and subretinal hemorrhages.

Because ICG is 98% bound to plasma proteins (principally lipoproteins and albumin), it remains largely intravascular within the fenestrated choriocapillaris, permitting high-definition visualization of the choroidal circulation.

ICG powder contains approximately 5% sodium iodide by weight; therefore, a documented severe allergy to iodine, shellfish anaphylaxis, or iodinated radiographic contrast constitutes an absolute contraindication.

ICG is eliminated exclusively by the hepatic system and excreted unchanged into bile without renal clearance, making it safe for patients with renal failure and dialysis dependence.

ICG angiography is the clinical gold standard for diagnosing polypoidal choroidal vasculopathy (PCV), delineating branching vascular networks and terminal aneurysmal polyps that may remain occult on fluorescein angiography.

Last updated: September 2026

Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology

Quick Summary: While sodium fluorescein angiography (FA) is optimal for evaluating the retinal circulation and the integrity of the inner blood-retinal barrier, indocyanine green angiography (ICGA) is the undisputed gold standard for visualizing the choroidal vasculature . Operating in the near-infrared spectrum ( 805 nm excitation / 835 nm emission ) with 98% plasma protein binding and exclusive hepatic excretion , ICG dye penetrates through RPE melanin, subretinal fluid, and hemorrhage to reveal deep chorioretinal pathology that remains completely invisible on conventional FA.

1. Biophysical Principles & Infrared Optical Physics

Indocyanine green ( C 43 H 47 N 2 N a O 6 S 2 C_{43}H_{47}N_{2}NaO_{6}S_{2} C 43 ​ H 47 ​ N 2 ​ N a O 6 ​ S 2 ​ , molecular weight 774.96 Da) is a water-soluble, amphiphilic tricarbocyanine dye. Its physical properties address the fundamental optical limitations that prevent fluorescein from effectively imaging the choroid:

The Near-Infrared Optical Window

Excitation Peak: 805 nm (near-infrared spectrum, in blood/plasma).

Emission Peak: 835 nm (near-infrared spectrum, in blood/plasma).

In contrast to fluorescein (excitation 465–490 nm, emission 520–530 nm in the visible spectrum), the near-infrared wavelengths of ICG confer three decisive optical advantages:

Melanin Transparency: The optical absorption of retinal pigment epithelium (RPE) melanin is high in the blue-green spectrum, absorbing up to 85% of fluorescein light. Above 800 nm, melanin absorption drops precipitously, rendering the RPE monolayer essentially translucent to near-infrared light.

Hemoglobin Transparency: Oxygenated and deoxygenated hemoglobin absorb visible blue-green light heavily. In the near-infrared window (>800 nm), hemoglobin absorption falls by more than an order of magnitude. Consequently, ICG excitation and emission photons penetrate directly through preretinal, intraretinal, and subretinal hemorrhages.

Reduced Optical Scattering: Longer wavelengths experience markedly less Rayleigh and Mie scattering from ocular media opacities, including mild nuclear cataracts, corneal haze, vitreous debris, and lipid/protein exudates.

Macromolecular Plasma Protein Binding

In circulating blood, 98% of ICG binds avidly to plasma proteins :

~80% binds to globulins and lipoproteins (high-density lipoproteins [HDL] and low-density lipoproteins [LDL]).

~20% binds to serum albumin.

In contrast, sodium fluorescein is only 60–80% loosely bound to albumin, leaving 20–40% free unbound dye .

Hemodynamic Impact: The choriocapillaris possesses large fenestrations (60–80 nm in diameter). Small free fluorescein molecules escape these pores almost instantaneously, producing a blinding, diffuse background "choroidal flush" that completely obscures the architectural details of choroidal vessels within 30 to 60 seconds. Because ICG is 98% locked into massive lipoprotein complexes, it remains largely intravascular , allowing sharp, high-contrast, long-duration imaging of the choroidal vessel architecture across all phases of the study.

Hepatic Clearance vs. Renal Excretion

Metabolism: ICG is taken up rapidly and selectively by hepatic parenchymal cells (hepatocytes) and excreted completely unchanged into the bile ; it is ultimately eliminated through the feces.

Zero Renal Elimination: There is no glomerular filtration or tubular secretion of ICG.

Clinical Safety Advantage: Unlike sodium fluorescein, which is cleared renally and requires caution or dialysis coordination in patients with end-stage renal disease (ESRD), ICG is safe in patients with renal failure and hemodialysis dependence . However, it is contraindicated in severe hepatic insufficiency or biliary cirrhosis.

Unlike fluorescein, ICG does not cause bright yellow-orange discoloration of the urine.

  • 2. Patient Safety, Dosage & Iodine Allergy Protocols
  • Reconstitution Protocol & Saline Hazard

ICG is supplied as a sterile lyophilized powder (typically 25 mg or 50 mg vials).

Mandatory Solvent: ICG must be dissolved strictly with the manufacturer-supplied sterile aqueous solvent (sterile water) .

Caution

NEVER Reconstitute ICG with Normal Saline: Reconstituting ICG with 0.9% sodium chloride (normal saline) or other halide-containing solutions causes immediate chemical precipitation of the dye , rendering it unusable and hazardous for intravenous injection. Once reconstituted with sterile water, the solution should be injected promptly because the dye begins to aggregate in aqueous solution over time.

The Iodine Allergy Contraindication

Commercial formulations of ICG powder contain approximately 5% sodium iodide by weight to ensure adequate chemical solubility and prevent molecular aggregation.

Warning

Absolute Allergy Contraindication: A documented history of severe allergy, urticaria, or anaphylaxis to iodine, shellfish (mollusks/crustaceans), or iodinated radiographic contrast media is an absolute contraindication to indocyanine green administration. Technologists must explicitly screen for iodine and shellfish allergies before reconstituting the vial.

Adverse Event Profile & Emergency Management

ICG is exceptionally well tolerated compared to sodium fluorescein:

Nausea and Vomiting: Occurs in less than 0.15% of ICG injections (compared to 5% to 10% with sodium fluorescein).

Severe Anaphylactoid Reactions: Extremely rare, occurring in approximately 1 in 40,000 to 1 in 300,000 administrations .

Preparation: Despite the low adverse event rate, institutional safety mandates that an emergency crash cart equipped with epinephrine (1:1,000 IM/SC) , diphenhydramine, methylprednisolone, supplemental oxygen, and suction equipment be immediately on hand during every ICGA procedure.

3. Transit Phases of Indocyanine Green Angiography

ICGA transit differs significantly from FA. Because ICG has a low fluorescence quantum yield (only ~4% that of fluorescein), high-sensitivity infrared digital sensors (or confocal scanning laser ophthalmoscopes [cSLO]) are required, and the study extends over 30 minutes :

1. Early Phase (0 to 60 Seconds)

Hemodynamics: Dye enters via the posterior ciliary arteries within 10–15 seconds post-injection. Large choroidal arteries (in Haller's layer ) and medium-sized vessels (in Sattler's layer ) fill rapidly. Choriocapillaris lobules fill in a mosaic pattern.

Retinal arterioles fill slightly after or concurrently with choroidal vessels, but appear dimmer than on FA due to rapid choroidal blood flow.

Diagnostic Target: Best phase to capture rapid transit, high-flow vascular loops, feeder vessels in CNV, and early polypoidal lesions.

2. Intermediate / Mid Phase (3 to 15 Minutes)

Hemodynamics: The large choroidal vessels begin to empty their dye into the vortex veins. The background choroidal glow becomes diffuse and homogeneous as dye slowly permeates the extravascular choroidal stroma. Retinal vascular lumens become faint.

Diagnostic Target: Ideal for visualizing choroidal hyperpermeability patches in pachychoroid spectrum disease, delineating the boundaries of occult CNV plaques, and detecting inflammatory choroidal hypofluorescent dark dots.

3. Late Phase (15 to 30+ Minutes)

The "Choroidal Inversion" Phenomenon: In normal eyes, intravascular dye has completely cleared from the large choroidal vessels. The large choroidal vessels now appear as dark, hypofluorescent silhouettes (negative contrast) against a faint, diffuse background hyperfluorescence produced by scleral and stromal dye retention.

Diagnostic Target: Abnormal structures that retain ICG dye—such as occult CNV "plaques" , persistent polyp margins, or chronic inflammatory granulomas—stand out with striking hyperfluorescent contrast against the inverted dark background.

  • 4. Key Clinical Indications & Choroidal Pathologies
  • Polypoidal Choroidal Vasculopathy (PCV)

Clinical Overview: A distinct subtype of neovascular AMD (frequently classified as Type 1 CNV variant or aneurysmal type 1 neovascularization), highly prevalent in Asian and African-descent populations. Characterized by recurrent subretinal hemorrhages and orange-red subretinal nodules.

The Diagnostic Gold Standard: On FA, PCV lesions are often totally obscured by thick subretinal blood or appear as non-specific occult leakage or fibrovascular PEDs. ICGA is mandatory for definitive diagnosis.

Classic ICGA Findings:

Branching Vascular Network (BVN): A network of abnormal, inner choroidal vessels visible in the early-to-mid frames.

Aneurysmal Polyps: Terminal, saccular dilatations at the borders of the BVN that light up with intense early hyperfluorescence ( "light-bulb polyps" ).

Late Behavior: Polyps display either late central wash-out with a hyperfluorescent rim ( "hypofluorescent halo" ) or persistent late staining.

Therapeutic Impact: ICGA precisely guides thermal laser photocoagulation or photodynamic therapy (PDT) with verteporfin to obliterate active polyps while sparing normal tissue.

Occult (Type 1) Choroidal Neovascularization

In neovascular AMD, Type 1 CNV resides beneath the RPE monolayer. On FA, it produces ill-defined late leakage of undetermined source.

On ICGA, occult CNV is classified into two distinct morphology patterns:

Focal "Hot Spot": A solitary, intense, well-demarcated hyperfluorescent focus ≤1 disc diameter that appears in the mid-to-late phases, representing a focal neovascular feeder vessel or micro-loop.

Late "Plaque": A well-circumscribed zone of late hyperfluorescence >1 disc diameter that illuminates in the 20-to-30-minute frames, delineating the true anatomical perimeter of the sub-RPE neovascular complex.

Central Serous Chorioretinopathy (CSCR) & Pachychoroid Disease

Pathophysiology centers on choroidal congestion and hyperpermeability associated with abnormally thickened choroid (pachychoroid) and dilated Haller layer veins ( pachyvessels ).

ICGA Findings:

Early-to-mid phase demonstrates dilated, engorged choroidal veins with delayed regional emptying.

Mid-phase reveals geographic patches of intense choroidal hyperpermeability (dye leaking from congested choriocapillaris into the stroma) that persist into late frames.

ICGA frequently uncovers subclinical areas of choroidal hyperpermeability in the asymptomatic contralateral eye, proving CSCR is a bilateral choroidal disease.

Inflammatory Chorioretinopathies (Posterior Uveitis)

Vogt-Koyanagi-Harada (VKH) Disease: Bilateral granulomatous panuveitis. ICGA demonstrates:

Delay in early choriocapillaris lobular filling.

Numerous regularly distributed hypofluorescent dark dots in the early-to-mid phases, representing non-perfused choriocapillaris lobules or focal granulomatous inflammatory stromal infiltrates.

Hyperfluorescent optic disc leakage in late frames.

Birdshot Chorioretinopathy: Oval, creamy fundus lesions show multiple hypofluorescent dark spots along the choroidal vessels on ICGA. These spots are far more numerous than the lesions visible on ophthalmoscopy, providing the most sensitive objective marker of active choroidal inflammation and therapeutic efficacy.

Multiple Evanescent White Dot Syndrome (MEWDS): Characteristic punctate hypofluorescent spots in late ICGA frames clustered around the fovea and peripapillary region.

5. Direct Comparative Matrix: Fluorescein (FA) vs. Indocyanine Green (ICGA)

The table below contrasts the fundamental characteristics of the two primary ophthalmic angiographic dyes:

  • Parameter Sodium Fluorescein Angiography (FA) Indocyanine Green Angiography (ICGA)
  • Chemical Family Synthetic xanthene hydrocarbon Water-soluble tricarbocyanine dye
  • Molecular Weight 376.28 Da 774.96 Da
  • Optical Spectrum Visible spectrum Near-infrared spectrum
  • Peak Excitation 465–490 nm (blue) 805 nm (near-infrared)
  • Peak Emission 520–530 nm (yellow-green) 835 nm (near-infrared)

Plasma Protein Binding 60%–80% (loosely bound to albumin; 20%–40% free dye ) 98% (avidly bound to lipoproteins & albumin; <2% free dye )

Choriocapillaris Fenestrations Escapes freely and immediately (diffuse blur) Retained intravascularly (crisp choroidal vessels)

Primary Vascular Bed Retinal circulation & inner blood-retinal barrier Choroidal circulation & deep choriocapillaris

Melanin Penetration Poor (RPE melanin absorbs up to 85% of light) Superior (melanin is translucent at 800+ nm)

Hemorrhage Penetration Poor (dense optical blocking by hemoglobin) Superior (hemoglobin absorption drops >10-fold)

Route of Elimination Renal (glomerular filtration; discolors urine) Hepatic (exclusive biliary secretion; feces)

  • Iodine Content 0% (No iodine) ~5% sodium iodide by weight
  • Key Contraindications Prior fluorescein anaphylaxis Severe iodine/shellfish allergy , severe hepatic failure
  • Typical Study Duration 10–15 minutes 20–35 minutes

Primary Clinical Roles Diabetic retinopathy, RVO, retinal vasculitis, classic CNV PCV, occult CNV, pachychoroid/CSCR, white dot uveitis

6. Clinical Pearls & Technologist Safety Rules

Important

Renal Failure Safety: Patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD) on hemodialysis can safely undergo ICGA because the dye is cleared entirely by the liver. In contrast, sodium fluorescein is cleared renally; if FA is performed on a dialysis patient, the yellow skin discoloration and residual circulating dye persist for days until the next dialysis cycle.

Caution

Never Forget the Solvent Check: Always verify the reconstitution fluid. Grabbing a 10 mL flush of normal saline out of habit will ruin the ICG vial immediately by precipitating the dye into flocculent aggregates. Always use the sterile aqueous diluent provided in the ICG kit.

Loading diagram... Clinical Selection Workflow: FA vs. ICGA